%0 Journal Article
%T TP53 in MDS and AML: Biological and clinical advances.
%A Zhao Y
%A Chen W
%A Yu J
%A Pei S
%A Zhang Q
%A Shi J
%A Huang H
%A Zhao Y
%J Cancer Lett
%V 588
%N 0
%D 2024 Apr 28
%M 38417666
%F 9.756
%R 10.1016/j.canlet.2024.216767
%X Recently, the WHO-5 and the ICC 2022 criteria have emphasized poor prognosis in AML/MDS patients with multi-hit TP53 mutations, whereas mutated TP53 plays a critical role in tumorigenesis, drawing substantial interest in exploring its biological behaviors. Diverse characteristics of TP53 mutations, including types, VAF, CNVs, allelic status, karyotypes, and concurrent mutations have been extensively studied. Novel potential targets and comprehensive treatment strategies nowadays are under swift development, owing to great advances in technology. However, accurately predicting prognosis of patients with TP53-mutated myeloid neoplasms remains challenging. And there is still a lack of effective treatment for those patients.